Long-term cardiovascular safety of fenfluramine in patients with Dravet syndrome treated for up to 3 years: Findings from serial echocardiographic assessments

•327 Dravet syndrome patients were treated with fenfluramine for a median 23.9 months.•Serial echocardiograms were used to monitor cardiac valve function during treatment.•No cases of valvular heart disease were observed during the study.